Vahe Bedian

Vahe co-founded Viridian Biosciences in 2020.  He previously served as founding CSO of Quellis Biosciences and Dianthus Therapeutics. Prior to that, Vahe served for 10 years at AstraZeneca focused on antibody therapeutics and immuno-oncology, most recently as Director, Biotherapeutics and Director, Search and Evaluation, Global Product and Portfolio Strategy. Previously, Vahe spent eight years at Pfizer where he helped establish the company’s biologics strategy across therapeutic areas, co-led discovery efforts for four INDs, and supported a Phase 3 program. 

Vahe started his career in academic research, serving as Director of the hybridoma and DNA sequencing core facilities at the University of Pennsylvania. Vahe holds a Ph.D. in Biophysics from SUNY Buffalo and a M.S. and B.S. in Physics from the American University of Beirut.